Multiple Myeloma

Arlo-cel achieved a high ORR and CR rate with durable responses and favorable safety in relapsed/refractory multiple myeloma.

Tarek Mouhieddine, MD, discusses data from a study of ferritin and ALC as biomarkers of response to bispecific antibodies in relapsed/refractory myeloma.

Teclistamab plus daratumumab improved progression-free and overall survival in relapsed/refractory multiple myeloma after 1 to 3 lines of therapy.

Tarek Mouhieddine, MD, discusses the use of ferritin and ALC as biomarkers of response to bispecific antibodies in relapsed/refractory multiple myeloma.

Marc S. Raab, MD, discusses updated MRD negativity and safety data with teclistamab plus SOC induction regimens in newly diagnosed multiple myeloma.

Joshua Richter, MD, discusses the use of next-generation CELMoDs to boost T-cell responses with bispecific antibodies or CAR T-cell therapy in myeloma.

The top 5 OncLive TV videos of the week cover insights in uterine leiomyosarcoma, myelofibrosis, polycythemia vera, breast cancer, and multiple myeloma.

The removal of REMS programs for approved CAR T-cell therapies could enable improved access and streamlined management of hematologic malignancies.

Daratumumab plus lenalidomide, with reduced exposure to dexamethasone, led to a PFS improvement in frail, newly diagnosed multiple myeloma.

Luqui Qiu, MD, discusses the efficacy and safety of eque-cel in patients with relapsed or refractory multiple myeloma.

Tarek Mouhieddine, MD, discusses the background and design of a study of correlates of response to bispecific antibodies in relapsed/refractory myeloma.

Paula Rodriguez-Otero, MD, discusses linvoseltamab’s potential role in the management of high-risk smoldering myeloma.

Andrew Yee, MD, discusses lenalidomide plus ixazomib,​ dexamethasone, and daratumumab in newly diagnosed multiple myeloma.

The FDA clears maintenance lurbinectedin combination in lung cancer, T-DxD sBLA in HER2-positive breast cancer is accepted for review, and more.

Here is your Q4 2025 preview spotlighting 10 FDA decisions to watch, including upcoming PDUFAs for belantamab mafodotin, revumenib, sevabertinib, and more.

The FDA approved Enoby and Xtrenbo, denosumab biosimilars referencing Prolia and Xgeva, respectively.

Hira Mian, MD, discusses findings from a dynamic frailty analysis conducted in transplant-ineligible patients with newly diagnosed multiple myeloma.

The top 5 OncLive TV videos of the week cover insights in solid tumors, breast cancer, pancreatic cancer, and multiple myeloma.

Imlunestrant joins the treatment arsenal for ESR1-mutated metastatic breast cancer, T-DXd doublet gets priority review in HER2+ breast cancer, and more.

Oliver Van Oekelen, MD, PhD, discusses how S100A8/A9 in promotes T-cell exhaustion and limits responses to bispecific antibody therapy in multiple myeloma.

The SCOPE score was predictive of response, toxicity, and survival outcomes in patients with relapsed/refractory myeloma receiving BCMA CAR T-cell therapy.

OncLive heard from myeloma experts about the biggest developments in the field at the 22nd Annual International Myeloma Society Meeting and Exposition.

IberDd improved MRD negativity rates vs DVd in patients with relapsed/refractory multiple myeloma.

Hans Lee, MD; and Nisha Joseph, MD, discuss the FDA approval of linvoseltamab for the treatment of patients with relapsed/refractory multiple myeloma.